Michael J. Overman, MD, professor of gastrointestinal and medical oncology at The University of Texas MD Anderson Cancer Center, discusses recent data reported at the 2018 ESMO Congress for the frontline combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in microsatellite instability-high metastatic colorectal cancer.
At 1 year, the progression-free survival was approximately 80% and the majority of patients had a response. This is dramatic activity to see in the frontline, Overman notes.
While the follow-up was early, the results thus far from the 45 patients enrolled are promising and demonstrate that immunotherapy agents and combinations should be considered earlier on, particularly in deficient mismatch repair populations.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
